Last Update 19 Feb 26

PSTV: Upcoming CNS Milestones And Diagnostics Rollout Will Drive Future Upside

Analysts have trimmed their average Plus Therapeutics price target by $2.50, citing updated assumptions around discount rates, profit margins and a higher future P/E multiple, while still maintaining their fair value estimate at $5.50.

Analyst Commentary

Bullish Takeaways

Bullish analysts point to enough upside against the current trading price to justify a fresh positive view, even after trimming inputs such as discount rates and profit margins.
The maintained fair value estimate of $5.50 suggests that, in their models, execution on the existing pipeline could still support a higher valuation than where the shares have recently traded.
Supportive research views frame recent target adjustments as fine tuning of assumptions rather than a shift in the underlying thesis, which may reassure investors focused on long term growth potential.
For readers, the combination of a bullish initiation and an unchanged fair value anchor signals that some on the Street still see room for upside if the company meets their expectations on timelines and clinical milestones.

Bearish Takeaways

Bearish analysts have lowered their individual price targets by $1.50 and $1, reflecting a more cautious stance on risk, profitability and valuation multiples.
These cuts highlight concerns that prior assumptions around margins and required returns may have been too optimistic, which can weigh on how investors frame potential risk and reward.
The use of higher discount rates in some models signals a focus on execution risk, particularly around the timing and success of future value drivers.
For investors, the spread between lower individual targets and the $5.50 fair value estimate underscores that the story carries meaningful uncertainty on both valuation and execution, even if the overall thesis remains intact in some models.

What's in the News

Plus Therapeutics outlined anticipated 2026 milestones for REYOBIQ and CNSide, including dose and interval definition in the ReSPECT LM Phase 2 trial, expected data readouts in the third and fourth quarters of 2026 for LM and glioblastoma studies, commercial manufacturing scale up for REYOBIQ, and initiation of the ReSPECT PBC pediatric brain cancer Phase 1 trial (company business update).
The company set commercialization goals for its CNSide CSF assay platform in the US, targeting coverage for 150 million lives across commercial payors, Medicare and Medicaid coverage, a commercial order rate above 1,250 tests per year, and an expanded portfolio of CSF tumor characterization tests (company business update).
Plus Therapeutics completed a Type B meeting with the FDA on the REYOBIQ pivotal trial strategy for leptomeningeal metastases, discussing potential use of overall survival as a primary endpoint, circulating tumor cells as a secondary endpoint, and a randomized controlled trial design using an intrathecal chemotherapeutic comparator (FDA Type B meeting summary).
The company has announced and later completed composite units offerings, including a US$24.98m announced offering of units and pre funded units and a completed US$15m composite units offering at US$0.38 per security with a US$0.0266 discount, adding new capital to the balance sheet (offering announcements).
Certain common stock, warrants, restricted stock units and stock options totaling 138,897,548 common shares equivalent are subject to a lock up agreement that runs from 13 January 2026 through 28 February 2026, which limits sales by directors and officers during that period (lock up disclosures).

Valuation Changes

Fair Value: The analyst fair value estimate is unchanged at $5.50.
Discount Rate: The discount rate has fallen slightly from 7.37% to 7.25%.
Revenue Growth: The modeled revenue growth assumption is effectively unchanged at around 99.05% in both the prior and updated views.
Net Profit Margin: The assumed profit margin has fallen modestly from 16.96% to 16.15%.
Future P/E: The future P/E multiple has risen slightly from 162.65x to 170.21x.

180 views

Key Takeaways

Strengthened financial position and leadership could drive clinical advancements, potentially boosting future revenue and improving earnings growth.
Advancements and strategic partnerships indicate significant market opportunities, enhancing revenue potential and profit margins through reduced costs and expanded markets.
High clinical trial investments, reliance on grant funding, and regulatory challenges could stress Plus Therapeutics' financial stability and delay revenue growth.

Catalysts

About Plus Therapeutics

A clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.What are the underlying business or industry changes driving this perspective?

The recent completion of a $15 million equity financing, alongside additional grant proceeds, has strengthened Plus Therapeutics' balance sheet, ensuring adequate funding through key milestones, enhancing the financial position and potentially leading to future earnings growth.
Recruitment of seasoned leadership with extensive experience in oncology and diagnostics can drive efficient execution of clinical development, which could positively impact revenue if new treatments are successfully brought to market.
Advancement of REYOBIQ’s clinical trials, including FDA orphan drug designation and Fast Track status for LM related to lung and breast cancer, suggests an expedited path to approval, potentially impacting future revenue streams.
The anticipated market entry of CNSide, a cancer testing platform, presents a significant market opportunity, with a potential increase in total addressable market by 2 to 4 times, which could boost future revenue and profit margins.
Strategic partnerships for drug production and supply chain optimization aim to meet future commercial demand for REYOBIQ, minimizing production costs and potentially improving net margins.

Plus Therapeutics Earnings and Revenue Growth

Plus Therapeutics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Plus Therapeutics's revenue will grow by 87.1% annually over the next 3 years.
Analysts are not forecasting that Plus Therapeutics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Plus Therapeutics's profit margin will increase from -357.9% to the average US Biotechs industry of 16.1% in 3 years.
If Plus Therapeutics's profit margin were to converge on the industry average, you could expect earnings to reach $5.6 million (and earnings per share of $0.05) by about September 2028, up from $-19.0 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 207.5x on those 2028 earnings, up from -2.4x today. This future PE is greater than the current PE for the US Biotechs industry at 15.5x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

Plus Therapeutics Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Plus Therapeutics continues to invest substantially in clinical trials, which has led to increased spending and an operating loss of $14.7 million for 2024. This trend, if continued, could negatively impact net margins and financial stability.
The company's reliance on grant revenue for funding its operations, such as the CPRIT, NIH, and Department of Defense grants, introduces a risk if future grant funding does not meet expectations, potentially impacting earnings and cash flow.
There are risks associated with the clinical development pathway and regulatory approval for REYOBIQ, given the complexities of aligning with the FDA for trial design, endpoints, and patient subtypes, which could delay commercialization and revenue generation.
The competitive landscape and evolving nature of CNS cancer treatment diagnostics could pose challenges for CNSide's market penetration, affecting projected revenue from its diagnostic platform.
To expand diagnostic operations, sales, and market access broadly across the U.S., substantial investments in the sales force and operational infrastructure are required, which could strain financial resources and affect future profitability and cash position.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $7.875 for Plus Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $20.5, and the most bearish reporting a price target of just $3.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $34.8 million, earnings will come to $5.6 million, and it would be trading on a PE ratio of 207.5x, assuming you use a discount rate of 6.8%.
Given the current share price of $0.46, the analyst price target of $7.88 is 94.2% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Plus Therapeutics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

PSTV: 15 Million Financing And Prefunded Warrants Will Drive Clinical Progress